Tables of Rules

PROTEASE INHIBITORS

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase strand transfer inhibitors

  Mutations associated with resistance Mutations associated with « possible resistance »
LPV/r
At least 4 mutations among: L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M [1, 2, 3, 13]
I47A [8, 9]
L76V [11, 12]
3 mutations among: L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M [1, 2, 3, 13]
ATV/RTV
300/100 mg QD
I50L [4]
N88S [20,21,22]
At least  3 mutations among: L10F/I/V, G16E, L33F/I/V, M46I/L, D60E, A71V/T, I84V, I85V, L90M [5, 7, 14, 23]
2 mutations among: L10F/I/V, G16E, L33F/I/V, M46I/L, D60E, A71V/T, I84V, I85V, L90M [5, 7, 14, 23]
TPV/RTV
500/200 mg BID
At least a score of + 3* :  M36I/L/V – F53L/W/Y + Q58E + H69I/K/N/Q/R/Y + L89I/M/R/T/V [6, 15]
A score of + 2*: M36I/L/V F53L/W/Y + Q58E + H69I/K/N/Q/R/Y + L89I/M/R/T/V [6, 15]

DRV/RTV**
600/100 mg BID



800/100 mg QD

At least 4 mutations among: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V [10, 16, 17, 18, 19]


2 mutations among: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V [10, 16, 17, 18, 19]
3 mutations among: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V [10, 16, 17, 18, 19]

LPV: lopinavir, ATV:atazanavir, TPV: tipranavir, DRV : darunavir, RTV: ritonavir.

For indinavir, saquinavir, nelfinavir and fosamprenavir refer to previous rules (See Archives, September 2017, version 27).

* Insufficient data for HIV-1 subtype non-B.
** Please note that rules are different for DRV/RTV 600/100 mg BID and 800/100 mg QD.

For DNA provirus, Impact of stop codons and G to A mutations on ARV resistance is unknown.